First published in 2010, the EULAR recommendations for the management of RA, the most frequent inflammatory rheumatic disease, have been relied upon by healthcare professionals and organisations ...
After the first 6 months of disease-modifying antirheumatic drugs (DMARDs) use in patients with rheumatoid arthritis (RA), most very abnormal results newly seen in long-term routine laboratory ...
Pediatric Rheumatologist Explains Many New Updates to ACR’s Juvenile Idiopathic Arthritis Guidelines
The new draft guidelines favor earlier DMARD therapy with ‘much decreased reliance on glucocorticoids that have several side effects in growing children,’ said rheumatologist Susan Shenoi, MS.
The European Alliance of Associations for Rheumatology – updated its recommendations on the treatment of rheumatoid arthritis (RA) with disease-modifying antirheumatic drugs (DMARD). The 2025 update ...
A scoping review published in Arthritis Care & Research compares existing recommendations for the use of disease-modifying anti-rheumatic drugs (DMARDs) in pregnancy and reproductive health for women ...
More than 80% of patients with newly diagnosed rheumatoid arthritis, who were using bridging therapy, successfully tapered ...
Joint pain is often dismissed as aging, overuse or a minor injury. But for some people it is the first sign of inflammatory ...
Juvenile idiopathic arthritis (JIA) encompasses a group of pediatric inflammatory arthritides that includes oligoarticular JIA, polyarticular JIA, systemic JIA, psoriatic JIA, and enthesitis-related ...
Worries have persisted that cancer survivors in remission might face increased recurrence risk when treated with biologic drugs for autoimmune disease. This Danish study of rheumatoid arthritis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results